title: [The use of apoptosis inducers in the therapy of experimental influenza infection and preventing of chronic post-influenza lung damage].
abstract: Influenza is a respiratory infection widely spread around the world. Influenza complications are various in nature and in most cases involve the excessive proliferation of cells in respiratory tract as a factor of pathogenesis. In the present work the efficacy of the use of apoptosis inducer 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalenecarboxylic acid (AHPN) for prophylaxis of chronic damage on the stage of post- influenza pneumonia has been studied. Mice were infected with influenza virus A/mallard/Pennsylvania/10218/84(H5N2) with further study of the level of influenza virus reproduction in the lungs, specific mortality of animals and morphology of the foci of post-influenza pneumonia on the 15th day post inoculation. AHPN was shown to decrease the infectious activity of the virus in the lungs by 1.2-1.5 log10 EID50/0.2 mL depending on the dose as compared to the control group, in a weak decrease in mortality of animals (protection index was 12.5-37.5%). The application of AHPN restricted both the proliferative and infiltrative component in chronic post-influenza lesions. It demonstrated the most pronounced effect on the lung morphology when applied on days 4 to 7 post inoculation, i. e. in the period of maximal activation of inflammatory tissue infiltration and regeneration of bronchiolar epithelium. In conclusion, the use of apoptosis inducers can partially prevent the development of chronic post-influenza lesions with proliferative component.
authors.forename: V V
authors.initials: VV
authors.lastname: Zarubaev
authors.forename: V G
authors.initials: VG
authors.lastname: Tribulovich
authors.forename: S V
authors.initials: SV
authors.lastname: Beliavskaia
authors.forename: N A
authors.initials: NA
authors.lastname: Barlev
authors.forename: O I
authors.initials: OI
authors.lastname: Kiselev
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000187:drug effects* / Q000473:pathology / Q000821:virology; D053125:Influenza A Virus, H5N2 Subtype / Q000187:drug effects / Q000254:growth & development; D008168:Lung / Q000187:drug effects* / Q000473:pathology / Q000821:virology; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011024:Pneumonia, Viral / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000473:pathology; D020545:Respiratory Mucosa / Q000187:drug effects* / Q000473:pathology / Q000821:virology; D012176:Retinoids / Q000494:pharmacology*; D016019:Survival Analysis; D013997:Time Factors; D019562:Viral Load / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; C099555:CD 437; D012176:Retinoids